NASDAQ:EBIO Eleven Biotherapeutics (EBIO) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free EBIO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume15.58 million shsAverage Volume2.86 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Eleven Biotherapeutics alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Eleven Biotherapeutics Stock (NASDAQ:EBIO)Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.Read More Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him EBIO Stock News HeadlinesDecember 2, 2023 | afr.com7-Eleven Australia’s family owners sell for $1.71bNovember 11, 2023 | mirror.co.ukEleven councillors quit Labour Party as Keir Starmer refuses to back Gaza ceasefireApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.August 16, 2023 | foxnews.comCalifornia mayor criticizes Prop 47 after 7-Eleven Sikh employees beat alleged thiefJuly 31, 2023 | usatoday.comFree Slurpees? Yes, here's how to get one today and Tuesday, 7-Eleven's 96th birthdayApril 9, 2023 | cbsnews.comChicago police close in on 7-Eleven robbery suspects in LawndaleJanuary 27, 2023 | dallasnews.comA downtown Dallas 7-Eleven that averaged one police call a day has closedJanuary 26, 2023 | nypost.comChef Daniel Humm’s all-vegan menu at Eleven Madison Park blossoms after rough patchApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.January 15, 2023 | abcnews.go.com7-Eleven adds new bright purple, zero-sugar Slurpee flavor to the mixJanuary 15, 2023 | foxnews.comEleven New Jersey police officers treated for fentanyl exposure during search, 5 suspects arrestedOctober 14, 2022 | finance.yahoo.com7-Eleven, Inc. Introduces Limited Time Only Green Apple Flavor to Slurpee LineupSeptember 27, 2022 | finance.yahoo.comAeglea BioTherapeutics, Inc. (AGLE)See More Headlines Receive EBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eleven Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2018Today4/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EBIO CUSIPN/A CIK1485003 Webwww.elevenbio.com Phone(617) 444-8550FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesThomas R. CannellPresident, Chief Executive Officer & DirectorMonica ForbesChief Financial Officer & TreasurerJeannick CizeauHead of ResearchGlen C. MacDonaldChief Technology OfficerKirstin N. AndersonSenior Director-FinanceKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors EBIO Stock Analysis - Frequently Asked Questions How were Eleven Biotherapeutics' earnings last quarter? Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) posted its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. What other stocks do shareholders of Eleven Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eleven Biotherapeutics investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Immunomedics (IMMU), Dynavax Technologies (DVAX), Sesen Bio (SESN), iShares Preferred and Income Securities ETF (PFF) and Inovio Pharmaceuticals (INO). This page (NASDAQ:EBIO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eleven Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
